Adjuvant therapy of XXXX with @entity900 , @entity2879 , and @entity1732 : a trial of the Gynecologic Oncology Group.

@entity1 @entity43 @entity12962 @entity137 @entity706 @entity5 @entity900 @entity2879 @entity3052 @entity6040 @entity1732 @entity44
PURPOSE: This study was performed to determine the effectiveness of postoperative adjuvant chemotherapy in @entity1 with surgically resected @entity43 . @entity1 AND METHODS: After @entity5 removal and thorough surgical staging, @entity1 were enrolled on this study and treated with three courses of @entity900 , @entity2879 , and @entity1732 ( @entity12962 ). Reassessment laparotomy was required of consenting, appropriate @entity1 initially, but became an optional procedure in 1989. RESULTS: Of 93 @entity1 assessable on this trial, 89 are continuously free of @entity5 . At second-look laparotomy, two other @entity1 were found to have small foci of @entity44 ; both remain clinically free of recurrence. One received subsequent alternate chemotherapy and one did not. Thus, 91 of 93 @entity1 are currently free of @entity5 . Follow-up duration ranges from 4.0 to 90.3 months, with 67 @entity1 monitored for longer than 2 years. Acute @entity137 was moderate. One @entity1 developed @entity6040 22 months after diagnosis. Another @entity1 was noted to have a @entity706 69 months after protocol treatment. CONCLUSION: Three courses of BEP will nearly always prevent recurrence in well-staged @entity1 with completely resected @entity43 and should be given to all such @entity1 . The development of @entity3052 as a complication of treatment is disturbing and mandates careful long-term follow-up, but is unusual and does not alter the risk-to-benefit ratio of treatment.
